Cargando…

Ospemifene's effects on lipids and coagulation factors: a post hoc analysis of phase 2 and 3 clinical trial data

OBJECTIVE: To evaluate the effect of ospemifene 60 mg on the lipid and coagulation parameters of postmenopausal women using data from five phase 2 and 3 clinical trials. METHODS: Data for lipids and coagulation factors for 2,166 postmenopausal women were pooled from five randomized, placebo-controll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Archer, David F., Altomare, Corrado, Jiang, Wei, Cort, Susannah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott-Raven Publishers 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617371/ https://www.ncbi.nlm.nih.gov/pubmed/28509812 http://dx.doi.org/10.1097/GME.0000000000000900

Ejemplares similares

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials
por: Simon, James A., et al.
Publicado: (2018)

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial
por: Archer, David F., et al.
Publicado: (2019)

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program
por: Constantine, Ginger D., et al.
Publicado: (2015)

Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
por: Goldstein, Irwin, et al.
Publicado: (2019)

Ospemifene for vulvar and vaginal atrophy: an overview
por: Palacios, Santiago
Publicado: (2020)

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
por: Archer, David F., et al.
Publicado: (2015)

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy
por: Nappi, R. E., et al.
Publicado: (2015)

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
por: Shin, Jae Jun, et al.
Publicado: (2017)

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy
por: Bruyniks, N., et al.
Publicado: (2016)

Effects of thrombomodulin alfa on hemostatic parameters in disseminated intravascular coagulation: Post hoc analysis of a phase 3 randomized controlled trial
por: Ito, Takashi, et al.
Publicado: (2020)

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
por: Palacios, Santiago, et al.
Publicado: (2016)

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial
por: Kirchhof, Paulus, et al.
Publicado: (2020)

Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases
por: Goldstein, Andrew T., et al.
Publicado: (2016)

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014)

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies
por: Salcedo, Félix Lugo, et al.
Publicado: (2020)

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study
por: Rodríguez, Silvia Pilar González
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
por: Blanco, Zuramis Estrada, et al.
Publicado: (2020)

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
por: Soe, Lin H, et al.
Publicado: (2013)

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz, Gregory T, et al.
Publicado: (2014)

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
por: López, Ana Rosa Jurado, et al.
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles
por: del Carmen Pingarrón Santofimia, María, et al.
Publicado: (2020)

Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use
por: Cagnacci, Angelo, et al.
Publicado: (2020)

Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study
por: Nordstrom, Beth L., et al.
Publicado: (2022)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

The Influence of Plasma Prekallikrein Oligonucleotide Antisense Therapy on Coagulation and Fibrinolysis Assays: A Post-hoc Analysis
por: Fijen, Lauré M., et al.
Publicado: (2022)

Effects of Ospemifene on Drug Metabolism Mediated by Cytochrome P450 Enzymes in Humans in Vitro and in Vivo
por: Turpeinen, Miia, et al.
Publicado: (2013)

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
por: Lilue, Mariella, et al.
Publicado: (2020)

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial
por: Constantine, G., et al.
Publicado: (2015)

Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study
por: De Rosa, Nicoletta, et al.
Publicado: (2017)

Ospemifene displays broad-spectrum synergistic interactions with itraconazole through potent interference with fungal efflux activities
por: Eldesouky, Hassan E., et al.
Publicado: (2020)

Potential contribution of haemoconcentration to changes in lipid variables with empagliflozin in patients with type 2 diabetes: A post hoc analysis of pooled data from four phase 3 randomized clinical trials
por: Lund, Søren S., et al.
Publicado: (2021)

Effect of Ospemifene on Densitometric and Plasma Bone Metabolism Biomarkers in Postmenopausal Women Reporting Vulvar and Vaginal Atrophy (VVA)
por: Maffei, Silvia, et al.
Publicado: (2022)

Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies
por: Smith, Timothy, et al.
Publicado: (2020)

Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2023)

Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials
por: Shigematsu, Takashi, et al.
Publicado: (2017)

Efficacy of remimazolam versus midazolam for procedural sedation: post hoc integrated analyses of three phase 3 clinical trials
por: Dao, Van-Anh, et al.
Publicado: (2022)

Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials
por: Ezzati, Ali, et al.
Publicado: (2022)

Posttreatment with Ospemifene Attenuates Hypoxia- and Ischemia-Induced Apoptosis in Primary Neuronal Cells via Selective Modulation of Estrogen Receptors
por: Pietrzak, Bernadeta A., et al.
Publicado: (2023)

Risk factors for overcorrection of severe hyponatremia: a post hoc analysis of the SALSA trial
por: Yang, Huijin, et al.
Publicado: (2022)

Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data
por: Jin, Jie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_milb3ipnbbq3prlcbpdth4n5ao